Jonathon Sedgwick, B.Sc. (Hons) Ph.D. born Perth Australia, is an Immunologist, educated at the University of Western Australia with post-doctoral education at the University of Oxford. His subsequent career included positions in academic research in Germany and Australia, Group Director Immunology at the biotech Company DNAX, in Palo Alto, California and 11 years with Eli Lilly and Company where he held a number of roles including Chief Scientific Officer, Cancer Inflammation Research; Managing Director and Chief Scientific Officer of Lilly’s Singapore Research Center, and Chief Scientific Officer, Autoimmunity Discovery. In November 2015, Dr. Sedgwick joined Boehringer Ingelheim, based at the Ridgefield CT USA research site. He holds the position of Vice President and Global Head Cancer Immunology and Immune Modulation Research. He has responsibility across four global sites for the development of the Immuno-oncology discovery and early clinical portfolio, and for immune-modulation research. Amongst his key contributions to the immunology field was the discovery with colleagues at DNAX of the dominant biological role of the interleukin-23 cytokine in autoimmune inflammation, and through this identifying the IL-17-producing T cell subset, Th17. These discoveries have underpinned a number of breakthrough medicines in the autoimmunity field. Dr. Sedgwick has authored or co-authored 120 peer-reviewed, review articles and book chapters.